Literature DB >> 34553295

Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase.

Dmitry Malin1, Yoonkyu Lee1, Olga Chepikova1,2, Elena Strekalova1, Alexis Carlson1, Vincent L Cryns3.   

Abstract

PURPOSE: Tumor cells are dependent on the glutathione and thioredoxin antioxidant pathways to survive oxidative stress. Since the essential amino acid methionine is converted to glutathione, we hypothesized that methionine restriction (MR) would deplete glutathione and render tumors dependent on the thioredoxin pathway and its rate-limiting enzyme thioredoxin reductase (TXNRD).
METHODS: Triple (ER/PR/HER2)-negative breast cancer (TNBC) cells were treated with control or MR media and the effects on reactive oxygen species (ROS) and antioxidant signaling were examined. To determine the role of TXNRD in MR-induced cell death, TXNRD1 was inhibited by RNAi or the pan-TXNRD inhibitor auranofin, an antirheumatic agent. Metastatic and PDX TNBC mouse models were utilized to evaluate in vivo antitumor activity.
RESULTS: MR rapidly and transiently increased ROS, depleted glutathione, and decreased the ratio of reduced glutathione/oxidized glutathione in TNBC cells. TXNRD1 mRNA and protein levels were induced by MR via a ROS-dependent mechanism mediated by the transcriptional regulators NRF2 and ATF4. MR dramatically sensitized TNBC cells to TXNRD1 silencing and the TXNRD inhibitor auranofin, as determined by crystal violet staining and caspase activity; these effects were suppressed by the antioxidant N-acetylcysteine. H-Ras-transformed MCF-10A cells, but not untransformed MCF-10A cells, were highly sensitive to the combination of auranofin and MR. Furthermore, dietary MR induced TXNRD1 expression in mammary tumors and enhanced the antitumor effects of auranofin in metastatic and PDX TNBC murine models.
CONCLUSION: MR exposes a vulnerability of TNBC cells to the TXNRD inhibitor auranofin by increasing expression of its molecular target and creating a dependency on the thioredoxin pathway.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Auranofin; Cancer; Glutathione; Methionine; Nutrition; Oxidative stress; Thioredoxin

Mesh:

Substances:

Year:  2021        PMID: 34553295      PMCID: PMC8793942          DOI: 10.1007/s10549-021-06398-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  52 in total

1.  Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.

Authors:  Elena Strekalova; Dmitry Malin; David M Good; Vincent L Cryns
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine.

Authors:  R M Hoffman; R W Erbe
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

3.  Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.

Authors:  William C Stafford; Xiaoxiao Peng; Maria Hägg Olofsson; Xiaonan Zhang; Diane K Luci; Li Lu; Qing Cheng; Lionel Trésaugues; Thomas S Dexheimer; Nathan P Coussens; Martin Augsten; Hanna-Stina Martinsson Ahlzén; Owe Orwar; Arne Östman; Sharon Stone-Elander; David J Maloney; Ajit Jadhav; Anton Simeonov; Stig Linder; Elias S J Arnér
Journal:  Sci Transl Med       Date:  2018-02-14       Impact factor: 17.956

Review 4.  Serine, glycine and one-carbon units: cancer metabolism in full circle.

Authors:  Jason W Locasale
Journal:  Nat Rev Cancer       Date:  2013-07-04       Impact factor: 60.716

5.  Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.

Authors:  H H Bailey; G Ripple; K D Tutsch; R Z Arzoomanian; D Alberti; C Feierabend; D Mahvi; J Schink; M Pomplun; R T Mulcahy; G Wilding
Journal:  J Natl Cancer Inst       Date:  1997-12-03       Impact factor: 13.506

6.  Reduced availability of endogenously synthesized methionine for S-adenosylmethionine formation in methionine-dependent cancer cells.

Authors:  D W Coalson; J O Mecham; P H Stern; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

7.  Antioxidants accelerate lung cancer progression in mice.

Authors:  Volkan I Sayin; Mohamed X Ibrahim; Erik Larsson; Jonas A Nilsson; Per Lindahl; Martin O Bergo
Journal:  Sci Transl Med       Date:  2014-01-29       Impact factor: 17.956

8.  Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma.

Authors:  Emilie Thivat; Marie-Chantal Farges; Franck Bacin; Michel D'Incan; Marie-Ange Mouret-Reynier; Eric Cellarier; Jean-Claude Madelmont; Marie-Paule Vasson; Philippe Chollet; Xavier Durando
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

9.  Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect.

Authors:  P H Stern; R M Hoffman
Journal:  J Natl Cancer Inst       Date:  1986-04       Impact factor: 13.506

Review 10.  Glutathione metabolism in cancer progression and treatment resistance.

Authors:  Ankita Bansal; M Celeste Simon
Journal:  J Cell Biol       Date:  2018-06-18       Impact factor: 10.539

View more
  1 in total

Review 1.  Targeting the methionine addiction of cancer.

Authors:  Joni C Sedillo; Vincent L Cryns
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.